Ethnicity-specific differences in L-arginine status in South African men

Journal of Human Hypertension

Volumn 26, Issue 12, 2012, Pages 737-743

  Glyn, M C ^a   Anderssohn, M ^b   Luneburg N ^b   Van Rooyen, J M ^a   Schutte, R ^a   Huisman, H W ^a   Fourie, C M T ^a   Smith, W ^a   Malan, L ^a   Malan, N T ^a   Mels, C M C ^a   Boger R H ^b   Schutte, A E ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

arterial compliance; blood pressure; ethnicity; L arginine

Indexed keywords

6 N,N' DIMETHYLARGININE; ARGININE; C REACTIVE PROTEIN; COTININE; CREATININE; GAMMA GLUTAMYLTRANSFERASE; N(G),N(G) DIMETHYLARGININE; REACTIVE OXYGEN METABOLITE; UREA;

ADULT; AGE; AGED; AMINO ACID BLOOD LEVEL; ARTERY COMPLIANCE; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CAUCASIAN; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; ETHNIC DIFFERENCE; ETHNICITY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MALE; NEGRO; NORMAL HUMAN; PROTEIN BLOOD LEVEL; PULSE WAVE; SOUTH AFRICA; SYSTOLIC BLOOD PRESSURE; UREA BLOOD LEVEL;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ARGININE; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; HYPERTENSION; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREVALENCE; RISK FACTORS; SOUTH AFRICA;

EID: 84869490762     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2011.103     Document Type: Article

References (60)

1. Ignarro L, Cirino G, Casini A, Napoli C. Nitic oxide as a signaling molecule in the vascular system: an overview. J Cardiovasc Pharmacol 1999; 6: 879-886.
2. Signorello MG, Pascale R, Leoncini G. Transport of L-arginine and nitric oxide formation in human platelets. Eur J Biochem 2003; 270(9): 2005-2012. (Pubitemid 36560822)
3. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415. (Pubitemid 18090241)
4. Wu G, Morris M. Arginine metabolism: nitric oxide and beyond. Biochem J 1998; 336: 1-17. (Pubitemid 28532555)
5. Cylwik D, Mogielnicki A, Buczko W. L-arginine and cardiovascular system. Pharmacol Rep 2005; 57(1): 14-22. (Pubitemid 40601537)
6. McKnight J, Satterfield M, Jobgen W, Smith S, Spencer T, Meininger C et al. Beneficial effects of L-arginine on reducing obesity: potential mechanisms and important implications for human health. Amino Acids 2010; 39(2): 349-357.
7. Michel T, Vanhoutte P. Cellular signaling and NO production. Pflugers Arch 2010; 459: 807-816.
8. Vallance P, Chan N. Endothelial function and nitric oxide: clinical relevance. Heart 2001; 85: 342-350. (Pubitemid 32973574)
9. Taddei S, Virdis A, Mattei P, Ghiadoni L, Sudano I, Salvetti A. Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients. Circulation 1996; 94(6): 1298-1303. (Pubitemid 26307256)
10. Böger RH. The pharmacodynamics of L-arginine. J Nutr 2007; 137(6 Suppl 2): 1650S-1655S. (Pubitemid 46855525)
11. Böger RH. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 2006; 38(2): 126-136.
12. Closs E, Basha F, Habermeier A, Forstermann U. Interference of L-arginine analogues with L-arginine transport mediated by the y carrier hCAT-2B. Nitric Oxide 1997; 1: 65-73. (Pubitemid 28078129)
13. Kielstein JT, Bode-Boger SM, Frolich JC, Ritz E, Haller H, Fliser D. Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. Circulation 2003; 107: 1891-1895. (Pubitemid 36444130)
14. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S et al. Endogenous nitric oxide synthase inhibitor. A novel marker of atherosclerosis. Circulation 1999; 99: 1141-1146. (Pubitemid 29120084)
15. Boger RH, Bode-Boger S, Szuba A, Tsao PS, Chan JR, Tangphao O et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 1842-1847. (Pubitemid 28509278)
16. Boger RH, Lentz SR, Bode-Boger SM, Knapp HR, Haynes WG. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocysteinemia in humans. Clin Sci 2001; 100: 161-167. (Pubitemid 32165360)
17. Stuhlinger MC, Oka RK, Graf EE, Schmolzer I, Upson BM, Kapoor O et al. Endothelial dysfunction induced by hyperhomocyst (e)inemia: Role of asymmetric dimethylarginine. Circulation 2003; 108: 933-938. (Pubitemid 37048221)
18. Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002; 287: 1420-1426. (Pubitemid 34250505)
19. Kiechl S, Lee T, Santer P, Thompson G, Tsimikas S, Egger G et al. Asymmetric and symmetric dimethylarginines are of similar predictive value for cardiovascular risk in the general population. Atherosclerosis 2009; 205: 261-265.
20. Rector T, Bank A, Mullen K, Tschumperlin L, Sih R, Pillai K et al. Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure. Circulation 1996; 93(12): 2135-2141.
21. Adams M, McCredie R, Jessup W, Robinson J, Sullivan D, Celermajer DS. Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease. Atherosclerosis 1997; 129(2): 261-269. (Pubitemid 27135328)
22. Maxwell AJ, Cooke JP. Cardiovascular effects of L-arginine. Curr Opin Nephrol Hypertens 1998; 7(1): 63-70. (Pubitemid 28037523)
23. Agulló L, Garćia-Dorado D, Inserte J, Paniagua A, Pyrhonen P, Llevadot J et al. L-arginine limits myocardial cell death secondary to hypoxia-reoxygenation by a cGMP-dependent mechanism. Am J Physiol 1999; 276(5 Pt 2): H1574-H1580. (Pubitemid 29246544)
24. Susic D, Francischetti A, Frohlich E. Prolonged L-arginine on cardiovascular mass and myocardial haemodynamics and collagen in aged spontaneously hypertensive rats and normal rats. Hypertension 1999; 33(1 Pt 2): 451-455. (Pubitemid 29065701)
25. Harrison D. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997; 100: 2153-2157. (Pubitemid 27500136)
26. Opie L, Seedat Y. Hypertension in sub-Saharan African populations. Circulation 2005; 112: 3562-3568. (Pubitemid 43739533)
27. Seedat Y. Hypertension in black South Africans. J Hum Hypertens 1999; 13: 96-103.
28. Steyn K, Kazenellenbogen J, Lombard C, Bourne LT. Urbanization and the risk for chronic diseases of lifestyle in the black population of the Cape Peninsula, South Africa. J Cardiovasc Risk 1997; 4: 135-142. (Pubitemid 27374965)
29. van Rooyen J, Kruger H, Huisman H, Wissing M, Margetts B, Venter C et al. An epidemiological study of hypertension and its determinants in a population in transition: the THUSA study. J Hum Hypertens 2000; 14: 779-787. (Pubitemid 32015829)
30. Thorogood M, Connor M, Tollman S, Hundt GL, Fowkes G, Marsh J. A cross-sectional study of vascular risk factors in a rural South African population: data from the South African Stroke Prevention Initiative (SASPI). BMC Public Health 2007; 7: 326-335.
31. Sliwa K, Wilkinson D, Hansen C, Ntyintyane L, Tibazarwa K, Becker A et al. Spectrum of heart disease and risk factors in a black urban population in South Africa (the Heart of Soweto Study): a cohort study. Lancet 2008; 371: 915-922. (Pubitemid 351375275)
32. Ix J, Allison M, Denenberg J, Cushman M, Criqui M. Novel cardiovascular risk factors do not completely explain the higher prevalence of peripheral arterial disease among African Americans. The San Diego Population Study. J Am Coll Cardiol 2008; 51: 2347-2354. (Pubitemid 351783358)
33. Melikian N, Wheatcroft S, Ogah O, Murphy C, Chowienczyk P, Wierzbicki A et al. Asymmetric dimethylarginine and reduced nitric oxide bioavailability in young Black African men. Hypertension 2007; 49: 873-877. (Pubitemid 351664208)
34. Steyn K, Sliwa K, Hawken S, Commerford P, Onen C, Damasceno A et al. Risk factors associated with myocardial infarction in Africa: the INTERHEART Africa study. Circulation 2005; 112: 3554-3561. (Pubitemid 43739532)
35. Lemogoum D, Van Bortel L, Leeman M, Degaute J, van de Borne P. Ethnic differences in arterial stiffness and wave reflections after cigarette smoking. J Hypertens 2006; 24: 683-689.
36. Heffernan K, Jae S, Fernhall B. Racial differences in arterial stiffness after exercise in young men. Am J Hypertens 2007; 20: 840-845. (Pubitemid 47176354)
37. Siekmeier R, Grammer T, März W. Roles of oxidants, nitric oxide, and asymmetric dimethylarginine in endothelial function. J Cardiovasc Pharmacol Ther 2008; 13: 279-297.
38. Cockroft D, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
39. Schwedhelm E, Tan-Andresen J, Maas R, Riederer U, Schulze F. Boger RH Liquid chromatography-tandem mass spectrometry method for the analysis of asymmetric dimethylarginine in human plasma. Clin Chem 2005; 51: 1268-1271. (Pubitemid 43079411)
40. Schwedhelm E, Maas R, Tan-Andresen J, Schulze F, Riederer U, Boger RH. High-throughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 851: 211-219. (Pubitemid 46720141)
41. Hayashi IY, Imai K, Nakamura M, Nakachi K, Hayashi T. High-throughput spectrophotometric assay of reactive oxygen species in serum. Mut Res 2007; 631: 55-61. (Pubitemid 46809621)
42. Marfell-Jones M, Olds T, Stewart A, Carter L (eds) International Standards for Anthropometric Assessment. International society for the Advancement of Kinanthropometry: Potchefstroom, South Africa, 2006.
43. Barỳs N, Erdogan M, Sezer E, Saygili F, Ozgonul A, Turgan N et al. Alterations in L-arginine and inflammatory markers in type 2 diabetic patients with and without microalbuminuria. Acta Diabetol 2009; 46: 309-316.
44. Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger R et al. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 2005; 46: 518-523. (Pubitemid 41040296)
45. McLaughlin T, Stuhlinger S, Lamendola C, Abbasi F, Bialek J, Reaven G et al. Plasma asymmetric dimethylarginine concentrations are elevated in obese insulin-resistant women and fall with weight loss. JCEM 2006; 91(5): 1896-1900.
46. Stamler J, Loh E, Roddy M, Currie K, Creager M. Nitic oxide regulates basal and pulmonary vascular resistance in healthy humans. Circulation 1994; 89: 2035-2040. (Pubitemid 24142778)
47. Sugawara J, Maeda S, Otsuki T, Tanabe T, Ajisaka R, Matsuda M. Effects of nitric oxide synthase inhibitor on decrease in peripheral arterial stiffness with acute low-intensity aerobic exercise. AJP-Heart 2004; 287: 2666-2669.
48. Baylis C. Nitric oxide deficiency in chronic kidney disease. Am J Physiol Renal Physiol 2008; 294: F1-F9.
49. Xu W, Kaneko F, Zheng S, Comhair S, Janocha A, Goggans T et al. Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J 2004; 18(14): 1746-1748. (Pubitemid 39561671)
50. Morris C, Poljakovic M, Lavrisha L, Machado L, Kuypers F, Morris S. Decreased arginine bioavailability and increased serum arginase activity in asthma. Am J Respir Crit Care Med 2004; 170: 148-153. (Pubitemid 38925160)
51. Chandra S, Romero M, Shatanawi A, Alkany A, Caldwell R, Caldwell R. Oxidative species increase arginase activity in endothelial cells through RhoA/Rho kinase pathway. Br J Pharmacol (e-pub ahead of print 8 July 2011; doi: 10.1111/j.1476-5381.2011.01584).
52. Xiao S, Wagner L, Mahaney J, Baylis C. Uremic levels of urea inhibit L-arginine transport in cultured endothelial cells. Am J Physiol 2001; 280(6): F989-F995.
53. Martens C, Edwards D. Peripheral vascular dysfunction in chronic kidney disease. Cardiol Res Pract 2011 (e-pub ahead of print 24 May 2011; doi:10.4061/2011/267257).
54. Mori M, Gotoh T. Arginine metabolic enzymes, nitric oxide and infection. J Nutr 2004; 134: 2820S-2825S. (Pubitemid 39315229)
55. Curis E, Nicolis I, Moinard C, Osowska S, Zerrouk N, Bénazeth S et al. Almost all about citrulline in mammals. Amino Acids 2005; 29: 177-205. (Pubitemid 41754486)
56. Romero MJ, Platt DH, Caldwell RB, Caldwell RW. Therapeutic use of citrulline in cardiovascular disease. Cardiovasc Drug Rev 2006; 24: 275-290. (Pubitemid 46435009)
57. Labadarios D, Steyn N, Maunder E, MacIntryre U, Gericke G, Swart R et al. The national food consumption survey (NFCS): South Africa, 1999. Public Health Nutr 2005; 8(5): 533-543. (Pubitemid 41431375)
58. Sydow K, Fortmann S, Fair J, Varady A, Hlatky M, Go A et al. Distribution of asymmetric dimethylarginine among 980 healthy, older adults of different ethnicities. Clin Chem 2010; 56: 1111-1120.
59. Schutte A, Schutte R, Huisman H, van Rooyen J, Fourie C, Malan L et al. Dimethylarginines: their vascular and metabolic roles in Africans and Caucasians. Eur J Endocrinol 2010; 162: 525-533.
60. Luft FC, Miller JZ, Grim CE, Fineberg NS, Christian JC, Daugherty SA et al. Salt sensitivity and resistance of blood pressure. Age and race as factors in physiological responses. Hypertension 1991; 17: I102-I108.